News

SPRIM PRO and ObvioHealth have announced an expansion of their partnership to provide a fully integrated trial solution.
ViiV's Cabenuva is administered every two months and was offered to HIV patients who achieved viral suppression from daily treatments.
The timing of the exposure during pregnancy made a big difference in the level of risk associated with developing an allergic condition.
MSD unveiled the launch of the Phase III trials of MK-8527 at the International AIDS Society (IAS) 2025 conference.
Amylyx has presented new exploratory analyses from the Phase II PREVENT and Phase IIb trials of avexitide for PBH treatment.
Verastem has reported primary analysis data from the Phase II RAMP 201 trial, where the avutometinib combination showed an ORR of 31% ...
Takeda’s oral narcolepsy drug, oveporexton, has met the primary and secondary endpoints in two Phase III trials. The FirstLight (NCT06470828) and RadiantLight (NCT06505031) trials both met all their ...
Findings from a Phase I trial initiated by Dana-Farber Cancer Institute have showed NeoVaxMI's improved immune response in melanoma patients.
Crinetics Pharmaceuticals has revealed new data from its clinical development programme for Palsonify, an oral treatment for acromegaly.
US-based MAIA Biotechnology has dosed the first subject in Taiwan in the expansion phase of its multicentre THIO-101 Phase II trial.
The US FDA has approved Purespring Therapeutics’ IND application for PS-002, allowing the company to begin a Phase I/II trial.
XyloCor has dosed the first subject in the multi-centre, randomised Phase IIb EXACT-2 trial to assess the gene therapy candidate, XC001.